BridgeBio Pharma, Inc.
BBIOAPI behind this page
BBIO FY 2025 request
Playground key active
/api/financials?ticker=BBIO&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue (FY) | — | — | — |
Show Product Lines breakouts |
|||
| Cost of license, services, and royalty revenue · Bayer | 93.8 | — | — |
| License And Service | 128,322 | 218,849 | -41.4% |
| License And Service · Alexion License Agreements | 33.3 | 0.6 | +5450.0% |
| License And Service · Kyowa Kirin Co., Ltd | 12.3 | 76.2 | -83.9% |
| License And Service · Reportable Segment | 128,322 | 218,849 | -41.4% |
| Product | 362,368 | 2,884 | +12464.8% |
| Product · Bayer | 7.6 | — | — |
| Product · Reportable Segment | 362,368 | 2,884 | +12464.8% |
| Royalty | 11,386 | 169 | +6637.3% |
| Royalty · Reportable Segment | 11,386 | 169 | +6637.3% |
Show Business Segments breakouts |
|||
| Reportable Segment | 502,076 | 221,902 | +126.3% |
Show — breakouts |
|||
| Revenue | 502,076 | 221,902 | +126.3% |
| Cost of Revenue (FY) | — | — | — |
Show Product Lines breakouts |
|||
| Cost of license, services, and royalty revenue | 5,275 | 2,436 | +116.5% |
| Cost of license, services, and royalty revenue · Reportable Segment | 5,275 | 2,436 | +116.5% |
| Product | 15,687 | 1,442 | +987.9% |
| Product · Reportable Segment | 15,687 | 1,442 | +987.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | 20,962 | 3,878 | +440.5% |
Show — breakouts |
|||
| Cost of Revenue | 20,962 | 3,878 | +440.5% |
| Research & Development (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 451,953 | 506,461 | -10.8% |
| Reportable Segment · Acoramidis for the treatment of ATTR-CM and primary prevention in asymptomatic carriers of a pathogenic TTR variant | 116,844 | 164,782 | -29.1% |
| Reportable Segment · BBP-418 for LGMD2I/R9 | 56,008 | 40,220 | +39.3% |
| Reportable Segment · Encaleret for ADH1 | 59,955 | 49,091 | +22.1% |
| Reportable Segment · Infigratinib for achondroplasia and hypochondroplasia | 122,685 | 91,869 | +33.5% |
| Reportable Segment · Other development programs | 22,703 | 71,732 | -68.4% |
| Reportable Segment · Other research programs | 73,758 | 88,767 | -16.9% |
Show — breakouts |
|||
| Research & Development | 451,953 | 506,461 | -10.8% |
Show Counterparty Name breakouts |
|||
| Gondola Bio, LLC · Transition Service Aggrement | 1.5 | 0.7 | +114.3% |
| Selling, General & Administrative (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 531,225 | 288,931 | +83.9% |
Show — breakouts |
|||
| Selling, General & Administrative | 531,225 | 288,931 | +83.9% |
| Restructuring Settlement And Impairment Provisions (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 21,347 | 15,605 | +36.8% |
Show — breakouts |
|||
| Restructuring Settlement And Impairment Provisions | 21,347 | 15,605 | +36.8% |
| Total Costs & Expenses (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 1,025,487 | 814,875 | +25.8% |
Show — breakouts |
|||
| Total Costs & Expenses | 1,025,487 | 814,875 | +25.8% |
| Operating Income (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | -523,411 | -592,973 | +11.7% |
Show — breakouts |
|||
| Operating Income | -523,411 | -592,973 | +11.7% |
| Interest Income (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 19,854 | 17,249 | +15.1% |
Show — breakouts |
|||
| Interest Income | 19,854 | 17,249 | +15.1% |
| Interest Expense (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | -53,103 | -90,991 | +41.6% |
Show — breakouts |
|||
| Interest Expense | -53,103 | -90,991 | +41.6% |
| Noncash Interest Expense On Deferred Royalty Obligations (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | -125,138 | -8,299 | -1407.9% |
| Reportable Segment · Related Party | -10,944 | — | — |
Show — breakouts |
|||
| Noncash Interest Expense On Deferred Royalty Obligations | -125,138 | -8,299 | -1407.9% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | -10,944 | — | — |
| Gains Losses On Extinguishment Of Debt (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | -21,155 | -26,590 | +20.4% |
Show — breakouts |
|||
| Gains Losses On Extinguishment Of Debt | -21,155 | -26,590 | +20.4% |
| Income Loss From Equity Method Investments (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | -72,608 | -31,183 | -132.8% |
Show — breakouts |
|||
| Income Loss From Equity Method Investments | -72,608 | -31,183 | -132.8% |
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts |
|||
| BridgeBio Oncology Therapeutics, Inc. | -37.5 | — | — |
| Gondola Bio, LLC | -35.1 | — | — |
| Other Non-Operating Income (Expense) (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 43,058 | 12,272 | +250.9% |
Show — breakouts |
|||
| Other Non-Operating Income (Expense) | 43,058 | 12,272 | +250.9% |
| Non-Operating Income (Expense) (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | -209,092 | 50,779 | -511.8% |
Show — breakouts |
|||
| Non-Operating Income (Expense) | -209,092 | 50,779 | -511.8% |
| Income Before Taxes (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | -732,503 | -542,194 | -35.1% |
Show — breakouts |
|||
| Income Before Taxes | -732,503 | -542,194 | -35.1% |
| Income Tax Expense (Benefit) (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 435 | 1,153 | -62.3% |
Show — breakouts |
|||
| Income Tax Expense (Benefit) | 435 | 1,153 | -62.3% |
| Net Income (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | -732,938 | -543,347 | -34.9% |
Show — breakouts |
|||
| Net Income | -732,938 | -543,347 | -34.9% |
| Net Income Loss Attributable To Noncontrolling Interest (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 8,007 | 7,585 | +5.6% |
Show — breakouts |
|||
| Net Income Loss Attributable To Noncontrolling Interest | 8,007 | 7,585 | +5.6% |
| Net Income Loss Available To Common Stockholders Basic (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | -724,931 | -535,762 | -35.3% |
Show — breakouts |
|||
| Net Income Loss Available To Common Stockholders Basic | -724,931 | -535,762 | -35.3% |
| EPS (Basic) (FY) | — | — | — |
Show — breakouts |
|||
| EPS (Basic) | -3.78 | -2.88 | -31.2% |
| EPS (Diluted) (FY) | — | — | — |
Show — breakouts |
|||
| EPS (Diluted) | -3.78 | -2.88 | -31.2% |
| Wtd Avg Shares (Basic) (FY) | — | — | — |
Show — breakouts |
|||
| Wtd Avg Shares (Basic) | 191,527,482 | 186,075,873 | +2.9% |
| Wtd Avg Shares (Diluted) (FY) | — | — | — |
Show — breakouts |
|||
| Wtd Avg Shares (Diluted) | 191,527,482 | 186,075,873 | +2.9% |
| Operating Expenses (FY) | — | — | — |
Show Counterparty Name breakouts |
|||
| BridgeBio Oncology Therapeutics, Inc. · Transition Service Aggrement | 0.5 | 0.7 | -28.6% |
| Gondola Bio, LLC · Transition Service Agreement And Sublease Agreement | 5.1 | 0.8 | +537.5% |
| Comprehensive Income (FY) | — | — | — |
Show — breakouts |
|||
| Comprehensive Income | -724,927 | -535,785 | -35.3% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents (Q) | — | — | — |
Show — breakouts |
|||
| Cash & Cash Equivalents | 570,119 | 681,101 | -16.3% |
| Available For Sale Securities Debt Securities Current (Q) | — | — | — |
Show — breakouts |
|||
| Available For Sale Securities Debt Securities Current | 17,363 | — | — |
| Accounts Receivable (Q) | — | — | — |
Show — breakouts |
|||
| Accounts Receivable | 139,444 | 4,722 | +2853.1% |
Show Counterparty Name breakouts |
|||
| Alexion License Agreements | 0.2 | 0.6 | -66.7% |
| Bayer | 5 | — | — |
| Inventory (Q) | — | — | — |
Show — breakouts |
|||
| Inventory | 26,753 | — | — |
| Prepaid Expenses & Other Current Assets (Q) | — | — | — |
Show — breakouts |
|||
| Prepaid Expenses & Other Current Assets | 44,070 | 34,869 | +26.4% |
Show Counterparty Name breakouts |
|||
| BridgeBio Oncology Therapeutics, Inc. · Transition Service Aggrement | 0.6 | 0.5 | +20.0% |
| Gondola Bio, LLC · Transition Service Agreement And Sublease Agreement | 4.5 | 3.2 | +40.6% |
| Total Current Assets (Q) | — | — | — |
Show — breakouts |
|||
| Total Current Assets | 797,749 | 720,692 | +10.7% |
| Non-Current Assets | |||
| Property, Plant & Equipment (Q) | — | — | — |
Show — breakouts |
|||
| Property, Plant & Equipment | 5,366 | 7,011 | -23.5% |
| Operating Lease Right-of-Use Assets (Q) | — | — | — |
Show — breakouts |
|||
| Operating Lease Right-of-Use Assets | 8,149 | 5,767 | +41.3% |
| Other Non-Current Assets (Q) | — | — | — |
Show — breakouts |
|||
| Other Non-Current Assets | 16,712 | 18,195 | -8.2% |
Show Counterparty Name breakouts |
|||
| BridgeBio Oncology Therapeutics, Inc. · Transition Service Aggrement | 7.8 | — | — |
| Total Assets (Q) | — | — | — |
Show — breakouts |
|||
| Total Assets | 936,025 | 919,338 | +1.8% |
| Intangible Assets (Q) | — | — | — |
Show — breakouts |
|||
| Intangible Assets | 28,077 | 23,926 | +17.3% |
| Other Assets | |||
| Equity Method Investments (Q) | — | — | — |
Show — breakouts |
|||
| Equity Method Investments | 79,972 | 143,747 | -44.4% |
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts |
|||
| BridgeBio Oncology Therapeutics, Inc. | 72.5 | 102.2 | -29.1% |
| Gondola Bio, LLC | 6.4 | 41.5 | -84.6% |
| Intangible Assets Net Excluding Goodwill (Q) | — | — | — |
Show — breakouts |
|||
| Intangible Assets Net Excluding Goodwill | 28,077 | 23,926 | +17.3% |
| Current Liabilities | |||
| Accounts Payable (Q) | — | — | — |
Show — breakouts |
|||
| Accounts Payable | 36,228 | 9,618 | +276.7% |
| Employee Related Liabilities Current (Q) | — | — | — |
Show — breakouts |
|||
| Employee Related Liabilities Current | 76,703 | 58,329 | +31.5% |
| Accrued Research And Development Liabilities Current (Q) | — | — | — |
Show — breakouts |
|||
| Accrued Research And Development Liabilities Current | 41,436 | 34,272 | +20.9% |
| Operating Lease Liability Current (Q) | — | — | — |
Show — breakouts |
|||
| Operating Lease Liability Current | 6,192 | 4,506 | +37.4% |
| Deferred Revenue (Current) (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Research and Development Services · Bayer | 0.8 | 1.3 | -38.5% |
Show — breakouts |
|||
| Deferred Revenue (Current) | 7,190 | 14,604 | -50.8% |
Show Counterparty Name breakouts |
|||
| Alexion License Agreements | 1 | 3 | -66.7% |
| Kyowa Kirin Co., Ltd | 5.4 | 10.3 | -47.6% |
| Other Liabilities Current (Q) | — | — | — |
Show — breakouts |
|||
| Other Liabilities Current | 120,222 | 33,071 | +263.5% |
Show Counterparty Name breakouts |
|||
| Gondola Bio, LLC · Transition Service Aggrement | 1.5 | 1.2 | +25.0% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 2,003 | — | — |
| Total Current Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Total Current Liabilities | 287,971 | 154,400 | +86.5% |
| Non-Current Liabilities | |||
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2027 Notes, net | 547,015 | 545,173 | +0.3% |
| 2029 Notes, net | 740,890 | 738,872 | +0.3% |
| 2031 Notes, net | 564,565 | — | — |
| Operating Lease Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Operating Lease Liabilities | 3,811 | 4,696 | -18.8% |
| Contract With Customer Liability Noncurrent (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Research and Development Services · Bayer | 2.1 | 2.2 | -4.5% |
Show — breakouts |
|||
| Contract With Customer Liability Noncurrent | 13,080 | 17,095 | -23.5% |
Show Counterparty Name breakouts |
|||
| Alexion License Agreements | 1.8 | — | — |
| Kyowa Kirin Co., Ltd | 9.2 | 14.9 | -38.3% |
| Other Non-Current Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Other Non-Current Liabilities | 244 | 286 | -14.7% |
| Total Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Total Liabilities | 3,012,606 | 2,376,950 | +26.7% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2027 Notes, net | 570,625 | — | — |
| 2027 Notes, net · Convertible Debt | 547,015 | 545,173 | +0.3% |
| 2029 Notes, net | 806,366 | — | — |
| 2029 Notes, net · Convertible Debt | 740,890 | 738,872 | +0.3% |
| 2031 Notes, net | 630,346 | — | — |
| 2031 Notes, net · Convertible Debt | 564,565 | — | — |
Show — breakouts |
|||
| Long-Term Debt | 2,007,337 | — | — |
| Other Liabilities | |||
| Deferred Royalty Obligation Net (Q) | — | — | — |
Show — breakouts |
|||
| Deferred Royalty Obligation Net | 855,030 | 479,091 | +78.5% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 204,650 | — | — |
Show Type Of Arrangement breakouts |
|||
| Funding Agreement | 548,055 | 479,091 | +14.4% |
| Royalty Purchase Agreement | 306,975 | — | — |
| Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests (Q) | — | — | — |
Show — breakouts |
|||
| Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests | -570 | 142 | -501.4% |
| Stockholders' Equity | |||
| Common Stock (Q) | — | — | — |
Show — breakouts |
|||
| Common Stock | 202 | 196 | +3.1% |
| Treasury Stock Common Value (Q) | — | — | — |
Show — breakouts |
|||
| Treasury Stock Common Value | -323,276 | -275,000 | -17.6% |
| Additional Paid-In Capital (Q) | — | — | — |
Show — breakouts |
|||
| Additional Paid-In Capital | 2,057,646 | 1,903,155 | +8.1% |
| Accumulated Other Comprehensive Income (Q) | — | — | — |
Show — breakouts |
|||
| Accumulated Other Comprehensive Income | 12 | 8 | +50.0% |
| Retained Earnings (Q) | — | — | — |
Show — breakouts |
|||
| Retained Earnings | -3,821,194 | -3,096,263 | -23.4% |
| Total Stockholders' Equity (Q) | — | — | — |
Show — breakouts |
|||
| Total Stockholders' Equity | -2,086,610 | -1,467,904 | -42.1% |
| Minority Interest (Q) | — | — | — |
Show — breakouts |
|||
| Minority Interest | 10,599 | 10,150 | +4.4% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 12 | 8 | +50.0% |
| Additional Paid In Capital | 2,057,646 | 1,903,155 | +8.1% |
| Common Stock | 202 | 196 | +3.1% |
| Noncontrolling Interest | 10,599 | 10,150 | +4.4% |
| Parent | -2,086,610 | -1,467,904 | -42.1% |
| Retained Earnings | -3,821,194 | -3,096,263 | -23.4% |
| Treasury Stock Common | -323,276 | -275,000 | -17.6% |
Show — breakouts |
|||
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -2,076,011 | -1,457,754 | -42.4% |
| Total Liabilities & Equity (Q) | — | — | — |
Show — breakouts |
|||
| Total Liabilities & Equity | 936,025 | 919,338 | +1.8% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation (FY) | — | — | — |
Show — breakouts |
|||
| Stock-Based Compensation | 133,024 | 95,800 | +38.9% |
| Amortization Of Financing Costs And Discounts (FY) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2027 Notes, net · Convertible Debt | 1,842 | 1,794 | +2.7% |
| 2029 Notes, net · Convertible Debt | 2,018 | 1,967 | +2.6% |
| 2031 Notes, net · Convertible Debt | 1,599 | — | — |
Show — breakouts |
|||
| Amortization Of Financing Costs And Discounts | 5,967 | 7,464 | -20.1% |
Show Long-Term Debt Type breakouts |
|||
| Convertible Debt | 5,459 | 3,761 | +45.1% |
| Depreciation & Amortization (FY) | — | — | — |
Show — breakouts |
|||
| Depreciation & Amortization | 5,434 | 6,075 | -10.6% |
| Operating Lease Right Of Use Asset Amortization Expense (FY) | — | — | — |
Show — breakouts |
|||
| Operating Lease Right Of Use Asset Amortization Expense | 4,902 | 4,110 | +19.3% |
| Embedded Derivative Gain Loss On Embedded Derivative Net (FY) | — | — | — |
Show — breakouts |
|||
| Embedded Derivative Gain Loss On Embedded Derivative Net | -19,652 | -1,550 | -1167.9% |
| Noncash Income Loss From Equity Method Investments (FY) | — | — | — |
Show — breakouts |
|||
| Noncash Income Loss From Equity Method Investments | -8,833 | — | — |
| Other Non-Cash Items (FY) | — | — | — |
Show — breakouts |
|||
| Other Non-Cash Items | -1,651 | -935 | -76.6% |
| Change in Accounts Receivable (FY) | — | — | — |
Show — breakouts |
|||
| Change in Accounts Receivable | -134,722 | -2,971 | -4434.6% |
| Change in Inventory (FY) | — | — | — |
Show — breakouts |
|||
| Change in Inventory | -25,307 | — | — |
| Change in Prepaid & Other Assets (FY) | — | — | — |
Show — breakouts |
|||
| Change in Prepaid & Other Assets | -8,777 | -13,918 | +36.9% |
| Increase Decrease In Other Operating Assets (FY) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Other Operating Assets | 1,113 | 1,542 | -27.8% |
| Change in Accounts Payable (FY) | — | — | — |
Show — breakouts |
|||
| Change in Accounts Payable | 26,609 | 1,512 | +1659.9% |
| Increase Decrease In Employee Related Liabilities (FY) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Employee Related Liabilities | 23,022 | 16,986 | +35.5% |
| Increase Decrease In Accrued Research And Development Liabilities (FY) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Accrued Research And Development Liabilities | 7,163 | 8,729 | -17.9% |
| Increase Decrease In Operating Lease Liability (FY) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Operating Lease Liability | -6,547 | -5,902 | -10.9% |
| Increase Decrease In Deferred Revenue (FY) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Deferred Revenue | -11,428 | 21,875 | -152.2% |
| Increase Decrease In Other Operating Liabilities (FY) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Other Operating Liabilities | 77,810 | 4,189 | +1757.5% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 2,003 | — | — |
| Net Cash from Operations (FY) | — | — | — |
Show — breakouts |
|||
| Net Cash from Operations | -445,910 | -520,726 | +14.4% |
| Change in Deferred Revenue (FY) | — | — | — |
Show — breakouts |
|||
| Change in Deferred Revenue | 150.1 | — | — |
| Investing Activities | |||
| Purchases of Investments (FY) | — | — | — |
Show — breakouts |
|||
| Purchases of Investments | -28,197 | -93,811 | +69.9% |
| Proceeds From Sale And Maturity Of Available For Sale Securities (FY) | — | — | — |
Show — breakouts |
|||
| Proceeds From Sale And Maturity Of Available For Sale Securities | 11,000 | 95,000 | -88.4% |
| Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital (FY) | — | — | — |
Show — breakouts |
|||
| Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital | 2,302 | 25,682 | -91.0% |
| Payments To Acquire Intangible Assets (FY) | — | — | — |
Show — breakouts |
|||
| Payments To Acquire Intangible Assets | -8,495 | -7,975 | -6.5% |
| Capital Expenditures (FY) | — | — | — |
Show — breakouts |
|||
| Capital Expenditures | -1,097 | -933 | -17.6% |
| Net Cash from Investing (FY) | — | — | — |
Show — breakouts |
|||
| Net Cash from Investing | -24,487 | 60,781 | -140.3% |
| Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest (FY) | — | — | — |
Show — breakouts |
|||
| Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest | -5,594 | -5,819 | +3.9% |
| Financing Activities | |||
| Proceeds From Convertible Debt (FY) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2031 Notes, net | 575,000 | — | — |
| Debt Issuance Costs (FY) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2031 Notes, net | -12,034 | — | — |
| Share Repurchases (FY) | — | — | — |
Show — breakouts |
|||
| Share Repurchases | -48,276 | — | — |
| Proceeds From Royalty Obligation (FY) | — | — | — |
Show Type Of Arrangement breakouts |
|||
| Royalty Interest Purchase and Sale Agreement | 300,000 | — | — |
| Issuance Costs And Discounts Associated With Royalty Obligation (FY) | — | — | — |
Show Type Of Arrangement breakouts |
|||
| Royalty Interest Purchase and Sale Agreement | -3,010 | — | — |
| Repayments Of Lines Of Credit (FY) | — | — | — |
Show — breakouts |
|||
| Repayments Of Lines Of Credit | -459,000 | -473,417 | +3.0% |
| Payment Of Deferred Royalty Obligation (FY) | — | — | — |
Show — breakouts |
|||
| Payment Of Deferred Royalty Obligation | -15,460 | — | — |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | -2,295 | — | — |
| Proceeds From Stock Plans (FY) | — | — | — |
Show — breakouts |
|||
| Proceeds From Stock Plans | 6,414 | 4,502 | +42.5% |
| Proceeds From Stock Options Exercised (FY) | — | — | — |
Show — breakouts |
|||
| Proceeds From Stock Options Exercised | 27,735 | 3,656 | +658.6% |
| Proceeds From Payments To Minority Shareholders (FY) | — | — | — |
Show — breakouts |
|||
| Proceeds From Payments To Minority Shareholders | 2,150 | — | — |
| Tax Withholding for Share Compensation (FY) | — | — | — |
Show — breakouts |
|||
| Tax Withholding for Share Compensation | -14,226 | -7,526 | -89.0% |
| Net Cash from Financing (FY) | — | — | — |
Show — breakouts |
|||
| Net Cash from Financing | 359,293 | 748,457 | -52.0% |
| Supplemental | |||
| Interest Paid (FY) | — | — | — |
Show — breakouts |
|||
| Interest Paid | 43,670 | 91,342 | -52.2% |
| Income Taxes Paid (FY) | — | — | — |
Show — breakouts |
|||
| Income Taxes Paid | 1,198 | — | — |
| Unpaid Capital Expenditures (FY) | — | — | — |
Show — breakouts |
|||
| Unpaid Capital Expenditures | 43 | 279 | -84.6% |
| Income Taxes Paid (FY) | — | — | — |
Show — breakouts |
|||
| Income Taxes Paid | 1,198 | — | — |
| Other Cash Flow | |||
| Net Change in Cash (FY) | — | — | — |
Show — breakouts |
|||
| Net Change in Cash | -111,104 | 288,512 | -138.5% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations (Q) | — | — | — |
Show — breakouts |
|||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 572,140 | 683,244 | -16.3% |
| Restricted Cash Current (Q) | — | — | — |
Show — breakouts |
|||
| Restricted Cash Current | 550 | 126 | +336.5% |
| Restricted Cash Noncurrent (Q) | — | — | — |
Show — breakouts |
|||
| Restricted Cash Noncurrent | 1,471 | 2,017 | -27.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents (Q) | — | — | — |
Show — breakouts |
|||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 572,140 | 683,244 | -16.3% |
Values in thousands USD. Source: SEC EDGAR 10-K filing.